XXXX for Good thank with our an pipeline Call. joining recent Financial our begin Results on then TRACON's I afternoon, will and you First and and update activities. Update Business Quarter review
March Following for the results discuss our that, financial Scott Brown, months our XX, ended Chief Financial Officer, will XXXX. X
questions. Finally, we conclude will your taking by
patients our continued the I with with from committee will C or interim update on pivotal planned was in Cohort April, ENVA XX and treatment. XX% of begin Phase safety by ongoing In data investigator recommended The by responses. as patients ENVASARC of independent progress review II with rate a continue an the central treated monitoring blinded review following independent and the review single-agent trial. NVA trial data efficacy in X.X% X single-agent objective response
was generally Enva single adverse well serious a monotherapy event. tolerated without drug-related
review response months. Importantly, median independent X than was by greater duration central
ENVA have with XX third report data the accrual a single milligrams of expect patients final in dosed at to completed quarter. and agent We XXX as
XX% objective reminder, refractory in treatment X to exceed a must response response responses objective the of confirmed ENVASARC only objective show or statistically rate central As review. primary the out rate patients MFS, for the order Votrient, UPS X% of by with an or in FDA-approved patients independent endpoint XX in
is endpoint. of response a X of key duration greater secondary months Median than
responses be to BLA both to independent liver than central warning more to approach demonstrate a for X plan that fatal Our review. by filing we has Votrient, the black goal potential with efficacious ENVA is and determine if a FDA in to box the strategy discuss safer toxicity.
We a drug ENVASARC
advantages the observed of sarcoma therapy to of refractory reminder, or in expedite based activity in tissue orphan review that regulatory and MFS on sarcoma lines provide important ENVA.
ENVASARC a designed on X in efficacy of have in These soft X of MFS. progressed safety data Fast ENVA Track for and drug sarcoma the designation subtypes designations have that designation UPS prior we and received UPS As subtypes might and received provide ENVASARC. is
ENVASARC common also for including and is UPS will a enrollment in ENVA the of initiate the strategy sarcoma the following to a We MFS, respond including the the have the trial therapy of completion of approval and of approved be of the in plan therefore, to used patients. goal newly doxorubicin. ENVA subject best subtypes of sarcoma. the of determine doxorubicin most the in to pursue frontline that sarcoma sarcoma treatment frontline to commonly the trial Doxorubicin We, expected diagnosed endpoint.
The to that trial subtypes achieving from combination positive ENVA to results ENVASARC, of pivotal and submission, primary the and BLA prior setting
require to the in randomized survival benefit. demonstrate trial, ENVASARC expect a results a will positive FDA the Assuming trial we pivotal
agent doxorubicin to as single doxorubicin trial and progression-free other with expect MFS and endpoint.
This as We survival to expected to UPS the patients well to expected compare sarcoma with post-approval be trial ENVA, III potential subtypes with Phase enroll will doxorubicin. respond ENVA as this with would therapy
anticipated in the MFS. in annual forecasted pivotal $XXX peak the positive potential of refractory trial.
It review to the for ENVASARC design and understand not revenues of from if sarcoma in potential the ENVASARC parity data the We time sarcoma, with to meeting submission is a frontline pricing is approval important sales the of with expected a refractory at discuss at to expect trial million assuming approved results pre-BLA ENVA ENVA of the accelerated UPS FDA in solely from
to designed for and supplemental benefit is ENVA neoadjuvant strategy by with to adjuvant in create seeking development patients BLAs. the settings clinical broadly the frontline, sarcoma opportunity Our
DNA to TRCXXX is Phase with and an endpoint from pipeline final now turn our financially lung now non-small independent TRCXXX Institute. inhibitor now cancer National of update a sites in in II product will our The our improvement are We that Stage non-squamous the results damage randomized to sponsoring for platform XX% cooperative discuss repair Cancer trial ongoing to in cell PFS X an are expected combination and clinical enrollment research NCI is CRO III, at shift supported assessing in standard development by with We of from of executed agreement treatment PDP open or trial through year of for chemo last CRO is therapy trial to to progression-free XX operations, implementation benefit radiation. consolidated recognized the designed reap detect November trial survival development maintenance in pemetrexed, will adding of biotech research. an XX%. enroll that at to of U.S. that to and year of upfront radiation durvalumab million will the of The a XX in patients TRCXXX of The is followed its X-arm and TRACON. independent license trial assess we treatment. the the value current care cisplatin primary our benefits PDP to payment $X company enjoy clinical the the internalizing XXXX.
I of a
trials to an for patient expected them the any oncology trials. we allow of as $XXX,XXX for TRACON, cost is estimated ] clinical per The at PDP license do approximately of for [
million to expected or indication, CRO charges in-house our partner by and trial approximately running trial of enrollment we that of a increased this advantages our patient from savings $XXX,XXX per As licensing PDP a speed typical $XX addition be execution XXX-patient trials in of TRACON potential enjoy on to a for the more pace using in team. could up
in have efficient we organizations. supplement clinical our position our independent further as CRO capital we nondilutive us cash one of most the for enabled believe As opportunities noted PDP development to past, through expect we the through that positions
potential leverage our continue expect X that We capital TRACON. to provide ways to to in nondilutive platform
plan to still but whereby First, a drug is in evaluate candidates, at at to Johnson. & model. fixed by we a revenue aligned to premium performing CRO, using to trials Johnson we clinical with used past, a the pay-for-performance TRACON captures our cost an for This cost a lower example, continue structure compared
continue we nontransferable Second, with to to we clinical clinical and new our another capabilities to licenses avoid these and enable execute to company to use to share plan contracting proprietary CROs capabilities trials. execute to operations our PDP paid independently, internalize whereby know-how are
earned for and the believe PDP been an such savings credibility for has investment substantial result believe at contracted as that at wish conducting compared become strong who higher CROs. partner.
We to and CRO-independent experience at As the trials in typically rewards we time, compelling our time companies and solution has cost of to our to TRACON, could cost over a quality lower reap trials faster
hearing us applicable a to X. we request hearing for As Hearings March had NASDAQ noncompliance previously the our NASDAQ X, to the plan NASDAQ to deficiencies with On contingent on market, compliance NASDAQ XX, announced, March regarding on continued XXXX, letter on compliance subject of deficiencies. that listing a all with XXXX, a cure Panel capital the we regaining June requirements. on regarding at listing granted our X received March X, We presented
us of will to or $XX of April at split X the million XX.
At listed deficiency Scott deficiencies our this for a least secure value which market cure other million requires stockholders' securities an update meet by $X.X have on requirement June equity time, provide financials. NASDAQ reverse of to NASDAQ X effected considering to the and the stock a We alternatives on are
